Literature DB >> 20182805

Effect of genetic variants of chemokine receptors on the development of myocardial infarction in Turkish population.

Zeynep Ermis Karaali1, Seyma Sozen, Melis Yurdum, Canan Cacina, Bahar Toptas, Ozlem Gok, Bedia Agachan.   

Abstract

Inflammation is a crucial component of coronary atherosclerosis and myocardial infarction (MI). Chemokine receptors are important modulators of inflammation. Polymorphisms in genes coding for chemokine receptors, CCR2 and CCR5, have been studied as genetic markers of coronary artery disease. In the present study, we investigated whether genetic variants of CCR2-V64I and CCR5-delta32 chemokine receptors have any effect on the development of myocardial infarction. A total of 146 MI patients and 202 control subjects were genotyped for CCR2 and CCR5. CCR2-V64I genotypes were not significantly different between patients with MI and controls (P > 0.05). CCR5-delta32 genotype distribution in cases was significantly different from that of controls (P = 0.042). The CCR5-delta32 wt/deletion genotype frequencies for controls and cases were 0.10 and 0.19, respectively and individuals with CCR5-delta32 wt/deletion genotype had a 2.13-fold increased risk of myocardial infarction (P = 0.0013). Individuals carrying the CCR5-delta32 heterozygote or homozygous variant genotype (deletion/deletion + wt/deletion) had a 1.96-fold increased risk of myocardial infarction compared with the wild-type genotype (wt/wt) (p: 0.016). In conclusion, our data have suggested that genetic variant of CCR5 might be associated with the development of MI. Further larger sample size studies are required to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182805     DOI: 10.1007/s11033-010-0011-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  6 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

2.  Prevalence of CCR5 and CCR2 HIV-coreceptor gene polymorphisms in Belgium.

Authors:  F Struyf; I Thoelen; N Charlier; E Keyaerts; I Van der Donck; J Wuu; M Van Ranst
Journal:  Hum Hered       Date:  2000 Sep-Oct       Impact factor: 0.444

3.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Authors:  M W Smith; M Dean; M Carrington; C Winkler; G A Huttley; D A Lomb; J J Goedert; T R O'Brien; L P Jacobson; R Kaslow; S Buchbinder; E Vittinghoff; D Vlahov; K Hoots; M W Hilgartner; S J O'Brien
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

4.  CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research.

Authors:  A O Anzala; T B Ball; T Rostron; S J O'Brien; F A Plummer; S L Rowland-Jones
Journal:  Lancet       Date:  1998-05-30       Impact factor: 79.321

Review 5.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

6.  C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome.

Authors:  Paolo Spagnolo; Elisabetta A Renzoni; Athol U Wells; Hiroe Sato; Jan C Grutters; Piersante Sestini; Atiyeh Abdallah; Enzo Gramiccioni; Henk J T Ruven; Roland M du Bois; Kenneth I Welsh
Journal:  Am J Respir Crit Care Med       Date:  2003-07-25       Impact factor: 21.405

  6 in total
  8 in total

1.  Association between chemokine receptor 5 (CCR5) delta32 gene variant and atherosclerosis: a meta-analysis of 13 studies.

Authors:  Zhongwen Zhang; Ju Liu; Huanjun Wang; Hongxia Wu; Xuanmei Wu; Jianjun Dong; Lin Liao
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Genetic variants of SDF-1 and CXCR4 genes in endometrial carcinoma.

Authors:  Canan Cacina; Sibel Bulgurcuoglu-Kuran; Ahmet Cem Iyibozkurt; Ilhan Yaylim-Eraltan; Bedia Cakmakoglu
Journal:  Mol Biol Rep       Date:  2011-05-24       Impact factor: 2.316

3.  Study of the association between growth differentiation factor 15 gene polymorphism and coronary artery disease in a Chinese population.

Authors:  Zhong Chen; Fangyi Xie; Genshan Ma; Yi Feng; Qi Qian; Naifeng Liu
Journal:  Mol Biol Rep       Date:  2011-02-11       Impact factor: 2.316

4.  Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.

Authors:  Arzu Ergen; Selim İsbir; Özlem Timirci; Atike Tekeli; Turgay İsbir
Journal:  Mol Biol Rep       Date:  2010-06-22       Impact factor: 2.316

5.  MCP-1 -2518 A/G functional polymorphism is associated with increased susceptibility to active pulmonary tuberculosis in Tunisian patients.

Authors:  Walid Ben-Selma; Hedi Harizi; Jalel Boukadida
Journal:  Mol Biol Rep       Date:  2011-03-08       Impact factor: 2.316

6.  Touch of chemokines.

Authors:  Xavier Blanchet; Marcella Langer; Christian Weber; Rory R Koenen; Philipp von Hundelshausen
Journal:  Front Immunol       Date:  2012-07-12       Impact factor: 7.561

7.  The CCR5Δ32 polymorphism in Brazilian patients with sickle cell disease.

Authors:  Mariana Pezzute Lopes; Magnun Nueldo Nunes Santos; Eliel Wagner Faber; Marcos André Cavalcanti Bezerra; Betânia Lucena Domingues Hatzlhofer; Dulcinéia Martins Albuquerque; Tânia Regina Zaccariotto; Daniela Maria Ribeiro; Aderson da Silva Araújo; Fernando Ferreira Costa; Maria de Fátima Sonati
Journal:  Dis Markers       Date:  2014-11-11       Impact factor: 3.434

Review 8.  Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.

Authors:  Anandi Rautenbach; Aurelia A Williams
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.